• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Belite Bio to Host Conference Call on August 11, 2022 to Discuss First Half 2022 Financial Results

    8/1/22 4:10:00 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BLTE alert in real time by email

    SAN DIEGO, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting untreatable eye diseases, will host a conference call on Thursday, August 11, 2022, at 4:30 p.m. Eastern time to discuss the Company's financial results for the first half, ended June 30, 2022, and provide a corporate progress update. The financial results will be issued in a press release on Wednesday, August 10, 2022.

    Belite Bio, Inc First Half 2022 Financial Result Conference Call Information:

    Date:Thursday, August 11, 2022
    Time:4:30 p.m. Eastern time (1:30 p.m. Pacific time)
    Webcast Link:https://edge.media-server.com/mmc/p/duiw3n7s
    Phone Registration Link:https://register.vevent.com/register/BI1ef44339069942b696cb9a1a54d14d41

    Webcast Link Instructions

    You can join a live webcast of the conference by visiting the "Webcast" link above or the "Presentations & Events" section of the Company's Investor Relations website at https://investors.belitebio.com/presentations-events/events. A reply will be available approximately two hours after the event for 30 days.

    Phone Registration Instructions

    To participate in the live call, please register using the "Phone Registration" link above. Once registered, you will receive dial-in numbers and unique PIN numbers via email. At the time of the call, you will dial in using the numbers from the confirmation email, and upon entering the unique PIN, will be routed into the call.

    About Belite Bio

    Belite Bio is a San Diego based clinical stage biopharmaceutical drug development company targeting untreatable eye diseases, such as atrophic age-related macular degeneration (commonly known as dry AMD) and Stargardt disease, and metabolic diseases. For more information, follow us the Company on Twitter, Instagram, LinkedIn, Facebook or visit us at www.belitebio.com.

    Important Cautions Regarding Forward Looking Statements

    This press release contains certain "forward-looking statements" within the meaning of federal securities laws. All statements, other than statements of historical facts, included herein are "forward-looking statements" including, among other things, statements about Belite's beliefs and expectations. The expectations reflected in these forward-looking statements involve significant assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Potential risks and uncertainties include, but are not limited to, risks discussed in Belite's filings with the U.S. Securities and Exchange Commission at www.sec.gov. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

    Media and Investor Relations Contact:

    Jennifer Wu /[email protected]

    Tim McCarthy /[email protected]



    Primary Logo

    Get the next $BLTE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BLTE

    DatePrice TargetRatingAnalyst
    12/14/2023$60.00Buy
    Maxim Group
    7/28/2023$43.00Overweight
    Cantor Fitzgerald
    7/26/2023$25.00Outperform
    SVB Securities
    8/1/2022$58.00Buy
    H.C. Wainwright
    More analyst ratings

    $BLTE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease

      Designation is based on the pivotal Phase 3 DRAGON trial interim analysis results demonstrating Tinlarebant's efficacy and favorable safety profileTrial completion expected by Q4 2025 (including a three-month follow-up period)Tinlarebant has previously been granted Fast Track and Rare Pediatric Disease Designations in the U.S., Orphan Drug Designation in the U.S., Europe, and Japan, and the Pioneer Drug Designation in Japan for Stargardt disease SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ:BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet med

      5/21/25 3:00:06 AM ET
      $BLTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

      NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Depositary Receipts Virtual Investor Conference ("dbVIC") held May 15th are now available for online viewing. VIEW PRESENTATIONS HERE The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company's resource section. May 15th Company Presentations Bavarian Nordic A/S ((Nasdaq Copenhagen: BAVA, OTC:BVNRY)Viomi Technology Co., Ltd. (NASDAQ:VIOT)Infineon Technologies AG ((Xetra: IFX, OTC:IFNNY)Clicks Group Ltd. ((JSE: CLS, OTC:CLCGY)First Paci

      5/16/25 8:35:00 AM ET
      $BLTE
      $COE
      $HCM
      $IH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Other Consumer Services
      Real Estate
    • Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Following a pre-specified interim analysis, an independent Data Safety Monitoring Board (DSMB) recommended the pivotal Phase 3 trial (DRAGON) of Tinlarebant in adolescent Stargardt disease (STGD1) patients proceed without any modification; trial completion expected Q4 2025 (including a three-month follow-up period)DSMB also recommended the Company submit the interim data for further regulatory review for drug approvalA pivotal global Phase 3 trial (PHOENIX) of Tinlarebant in geographic atrophy (GA) patients is ongoing with 464 of targeted 500 subjects enrolledRaised $15 million in gross proceeds in a registered direct offering on February 5, 2025Conference call and webcast on Wednesday, May

      5/13/25 9:00:36 PM ET
      $BLTE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLTE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Belite Bio with a new price target

      Maxim Group initiated coverage of Belite Bio with a rating of Buy and set a new price target of $60.00

      12/14/23 8:06:18 AM ET
      $BLTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Belite Bio with a new price target

      Cantor Fitzgerald initiated coverage of Belite Bio with a rating of Overweight and set a new price target of $43.00

      7/28/23 7:14:28 AM ET
      $BLTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Securities initiated coverage on Belite Bio with a new price target

      SVB Securities initiated coverage of Belite Bio with a rating of Outperform and set a new price target of $25.00

      7/26/23 7:15:36 AM ET
      $BLTE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLTE
    Leadership Updates

    Live Leadership Updates

    See more
    • Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer

      Dr. Scholl is a globally recognized leader in the field of ophthalmology and the coordinating principal investigator of the largest ever natural history study of Stargardt disease SAN DIEGO, Sept. 01, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio" or the "Company"), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its board of directors has appointed Hendrik P. N. Scholl, MD, MA, as the Chief Medical Officer of the Company, effective immediately. Dr. Scholl is the foremost globally recognized authority on Stargar

      9/1/24 8:00:00 AM ET
      $BLTE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLTE
    SEC Filings

    See more
    • SEC Form 6-K filed by Belite Bio Inc

      6-K - BELITE BIO, INC (0001889109) (Filer)

      5/21/25 6:01:12 AM ET
      $BLTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Belite Bio Inc

      6-K - BELITE BIO, INC (0001889109) (Filer)

      5/13/25 9:23:28 PM ET
      $BLTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Belite Bio Inc

      6-K - BELITE BIO, INC (0001889109) (Filer)

      4/15/25 4:00:44 PM ET
      $BLTE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLTE
    Financials

    Live finance-specific insights

    See more
    • Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

      Dosed first patient in Phase 2/3 DRAGON II trial of Tinlarebant for the treatment of Stargardt disease (STGD1)Pivotal global Phase 3 PHOENIX trial of Tinlarebant in geographic atrophy (GA) subjects is ongoing with more than 280 subjects enrolledAppointed Hendrik P.N. Scholl, MD, MA, a globally recognized leader in the field of ophthalmology and the coordinating principal investigator of the largest natural history study of Stargardt disease, as Chief Medical OfficerInterim analysis from the pivotal global Phase 3 DRAGON trial of Tinlarebant in adolescent STGD1 subjects anticipated by end of 2024 or early 2025Company to host webcast on Tuesday, November 12, 2024, at 4:30 p.m. EST SAN DIEGO,

      11/12/24 1:00:25 AM ET
      $BLTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results

      Completed enrollment in pivotal Phase 3 "DRAGON" trial for Tinlarebant in adolescent Stargardt disease ("STGD1") with 104 subjects enrolled across 11 countries worldwideFirst subject dosed with Tinlarebant in pivotal global Phase 3 "PHOENIX" trial in Geographic Atrophy ("GA")Oral, once-daily Tinlarebant continues to be safe and well tolerated, slowing expansion of autofluorescence, reducing incident atrophic retinal lesion growth rate, and stabilizing visual acuity up to 24-months in Phase 2 STGD1 trial ("LBS-008-CT02")Interim Phase 3 safety and efficacy data from pivotal "DRAGON" trial expected in 2H 2024Conference Call and Webcast Tuesday, November 14, 2023, at 4:30 p.m. ET

      11/13/23 8:15:47 PM ET
      $BLTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Belite Bio Reports First-Quarter 2023 Operational Highlights and Financial Results

      In 18-month interim data from ongoing 2-year, Phase 2 Stargardt disease ("STGD1") trial ("LBS-008-CT02"), we continued to observe that oral Tinlarebant is safe and well tolerated in adolescent STGD1 subjectsA continued trend of slowing expansion of autofluorescence was observed and the growth rate of incident atrophic retinal lesions was reduced with Tinlarebant in LBS-008-CT02 compared to a natural history study of the disease ("ProgStar")Stabilization of visual acuity with no significant loss and no clinically significant changes in retinal thickness observed over 18 months of treatment with Tinlarebant in LBS-008-CT0258 subjects have been enrolled in the pivotal Phase 3 "DRAGON" trial eva

      5/10/23 7:58:59 PM ET
      $BLTE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLTE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Belite Bio Inc

      SC 13G - BELITE BIO, INC (0001889109) (Subject)

      2/12/24 9:08:25 PM ET
      $BLTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Belite Bio Inc

      SC 13G - BELITE BIO, INC (0001889109) (Subject)

      2/12/24 8:40:46 PM ET
      $BLTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Belite Bio Inc

      SC 13G - BELITE BIO, INC (0001889109) (Subject)

      2/15/23 1:36:20 PM ET
      $BLTE
      Biotechnology: Pharmaceutical Preparations
      Health Care